Although the introduction of ABL-directed inhibitors, commonly named TKIs, induced long-term survival of CML patients, about 50% of them and patients affected by Ph+ B-ALL do not completely benefit from these drugs, often requiring an additional therapeutic approach [4]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.